12 Dec 2017

N+1 Singer - Morning Song 12-12-2017

Centaur Media plc (CAU:LON), 41.5 | Elementis plc (ELM:LON), 163 | Abzena (ABZA:LON), 0 | Realm Therapeutics (RLM:LON), 0 | Diales Group PLC (DIAL:LON), 17.5 | Servoca (SVCA:LON), 0 | Davide Campari-Milano N.V. (0ROY:LON), 0

- Singer CM Team
- 17 pages

Abzena (ABZA LN) Recent contract wins support H2 weighting | Carpetright (CPR LN) Disappointing miss in Europe undermines strategic progress in UK | Centaur Media (CAU LN) Trading in-line & new Chairman appointed | Driver Group (DRV LN) Focus on core business delivering results | Elementis (ELM LN) Sale of Surfactants for €39m | Ergomed (ERGO LN) Co-development agreement with Allergy Therapeutics | Realm Therapeutics (RLM LN) Phase II trial start in Allergic Conjunctivitis | Servoca (SVCA LN) Cr ....

Sign up to access

Get access to our full offering from over 30 providers

Get access to our full offering from over 30 providers

N+1 Singer - Morning Song 12-12-2017

Centaur Media plc (CAU:LON), 41.5 | Elementis plc (ELM:LON), 163 | Abzena (ABZA:LON), 0 | Realm Therapeutics (RLM:LON), 0 | Diales Group PLC (DIAL:LON), 17.5 | Servoca (SVCA:LON), 0 | Davide Campari-Milano N.V. (0ROY:LON), 0

Published: 12 Dec 2017
Author: Singer CM Team
Pages: 17

Abzena (ABZA LN) Recent contract wins support H2 weighting | Carpetright (CPR LN) Disappointing miss in Europe undermines strategic progress in UK | Centaur Media (CAU LN) Trading in-line & new Chairman appointed | Driver Group (DRV LN) Focus on core business delivering results | Elementis (ELM LN) Sale of Surfactants for €39m | Ergomed (ERGO LN) Co-development agreement with Allergy Therapeutics | Realm Therapeutics (RLM LN) Phase II trial start in Allergic Conjunctivitis | Servoca (SVCA LN) Cr ....

Top